Palantir Stock Rises 0.69% to $136.47 as UK Launches Full Review of NHS Contract

Palantir stock is showing resilience on June 9, 2026, even as a significant political risk escalates in the UK. Britain launched a full review of its £330 million ($441 million) NHS Federated Data Platform contract with Palantir, with Technology Minister Liz Kendall announcing the review will assess whether to extend the deal for up to seven years or terminate it using a 2027 break clause.

The announcement follows weeks of parliamentary pressure and adds direct uncertainty to Palantir’s UK revenue pipeline. Despite the noise, Palantir’s Q1 2026 revenue surged 85% year-over-year to $1.633 billion, a fundamental base that continues to underpin the stock.

What the UK NHS Review Actually Covers

A Labour-led UK parliamentary committee urged the government to remove Palantir from the £330 million NHS contract, citing privacy concerns, national data security risks, and a perceived mismatch with British values. The review is now formal and government-led, not just parliamentary commentary.

The Three Risks Driving the Review

• Patient data access: The Financial Times reported NHS officials had proposed granting Palantir personnel broad administrative access to identifiable patient data on parts of the system.
• London police contract blocked: Mayor Sadiq Khan separately blocked a £50 million Metropolitan Police contract with Palantir in May, citing ethics concerns in public procurement.
• MOD scrutiny added: UK Parliament is also reviewing a £240 million Ministry of Defence contract with Palantir, widening the regulatory risk beyond healthcare.
• Insider selling flagged: Palantir insiders sold $422.5 million in shares over the past three months, a data point the market is watching alongside the UK headlines.

Palantir Stock: Fundamentals vs. Political Risk

The tension between Palantir’s financials and its political exposure defines the current stock setup. Palantir raised its full-year 2026 revenue forecast to between $7.650 billion and $7.662 billion, implying 71% growth from 2025. US commercial revenue alone is anticipated to exceed $3.224 billion, representing growth of at least 120%. The UK contracts represent a fraction of that total, but the reputational risk in public sector AI is harder to quantify.

Deal Pipeline Signals Demand Holds Strong

Palantir reported 206 deals worth at least $1 million in Q1 2026, including 47 agreements of $10 million or more. These numbers that confirm the US government and commercial pipeline remains intact regardless of UK developments. Peer AI infrastructure names including Palantir (PLTR), C3.ai (AI), and BigBear.ai (BBAI) are all sensitive to government contract news, making today’s UK review a sector-wide watchpoint.

Key Takeaways

• UK launched a formal review of Palantir’s £330 million ($441 million) NHS contract on June 9
• Technology Minister Liz Kendall confirmed the review covers an extension up to 7 years or termination via a 2027 break clause
• London Mayor blocked a separate £50 million Palantir police contract in May
• Q1 2026 revenue hit $1.633 billion, up 85% year-over-year
• Full-year 2026 revenue guidance: $7.650–$7.662 billion, implying 71% growth
• Insider selling totaled $422.5 million over the past three months

Palantir stock’s resilience today reflects how the market is pricing US growth against UK political risk, and right now, the $1.633 billion quarterly revenue number is winning that argument. Live PLTR price data is tracked at nasdaq.com.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.